Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
598 of 1585



Newsletter Sign Up

Daily Readings

Reading 1, Ephesians 4:1-6
I, the prisoner in the Lord, urge you therefore to lead a life ... Read More

Psalm, Psalms 24:1-2, 3-4, 5-6
[Psalm Of David] To Yahweh belong the earth and all it ... Read More

Gospel, Luke 12:54-59
He said again to the crowds, 'When you see a cloud looming up ... Read More

Saint of the Day

October 24 Saint of the Day

St. Anthony Mary Claret
October 24: Claretian archbishop and founder. Anthony was born in Salient in ... Read More